{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-056599","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-05-14T20:05:34+00:00","discovered_at":"2026-05-14T20:07:00.245507+00:00","generated_at":"2026-05-14T21:01:31.523135+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA grants Fast Track designation to INmune Bio's XPro for early Alzheimer's disease","bullets":["Fast Track covers XPro for early Alzheimer's disease (MCI due to AD and mild AD dementia).","XPro is a selective soluble TNF inhibitor targeting neuroinflammation; no approved therapy targets this pathway.","Designation provides more frequent FDA interactions and eligibility for Rolling Review.","Phase 2b/3 registrational trial planned as seamless adaptive design using EMACC and pTau217."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-056599","json":"https://secwatch.observer/filing/0001213900-26-056599.json","markdown":"https://secwatch.observer/filing/0001213900-26-056599.md","text":"https://secwatch.observer/filing/0001213900-26-056599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026056599/0001213900-26-056599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026056599/ea0290846-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:01:31.523135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}